inflammatory drugs.
Vogelzang NJ, et al.JCO 2003, 21( 14 ): 2636-2644
Vogelzang NJ, et al.JCO 2003, 21( 14 ): 2636-2644
Vogelzang NJ, et al.JCO 2003, 21( 14 ): 2636-2644
2.9% 1.5% 1.1% 0.9%
表一 Butchart 分期
期别 I期 II期 III期
IV期
病变范围 病变局限在由壁层胸膜腔内,可侵及同侧胸膜、肺、 横膈以及胸膜返折以内的壁层心包; 病变侵犯胸壁、纵隔组织, 包括食管、心脏、气管、 大血管, 伴有或不伴有胸膜腔内淋巴结侵犯;
病变通过膈肌侵犯腹腔或腹膜后间隙, 或者侵犯对侧胸膜, 或伴有胸膜腔外淋巴结侵犯; 远处血行转移
Chest 1995, 108(4):1122.
影响预后的因素
Rusch VW,et al.J. of Thorac. & Cardiovasc. Surg. 122( 4) 788-795
影响预后的因素
Rusch VW,et al.J. of Thorac. & Cardiovasc. Surg. 122( 4) 788-795
Phase III trial of chemo Eligibility
• histologically proven • Chemotherapy-naive patients • not eligible for curative surgery • uni- or bidimensionally measurable disease • age 18 years with life expectancy 12 weeks • KPS no less than 70. • no second primary malignancy • no brain metastases • excluded if unable to interrupt nonsteroidal anti-